aTyr Pharma, Inc. (ATYR) Cash Flow Statement
Where ATYR’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$62.0M
- Capital expenditures
- $77,000 40.5% of revenue
- Free cash flow
- −$62.1M −32,664.7% margin
- Returned to shareholders
- —
- Change in cash
- −$1.0M cash at year-end $13.0M
Cash from operations
−$62.0M
Investments (net)
−$5.0M
Net borrowing (repayment)
−$539,000
Shares issued
+$66.4M
Change in cash
−$1.0M
Drawn to scale: where the cash came from and how it was used. Hover for values.
ATYR operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
ATYR cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$52.9M2016 | −$62.0M2025 | — | |
| Capital expenditures | $600,0002016 | $77,0002025 | −20.4%/yr | |
| Free cash flow | −$53.5M2016 | −$62.1M2025 | — | |
| Free cash flow margin | −4,761.1%2019 | −32,664.7%2025 | −27,903.6 pts | |
| Stock-based compensation | $1.8M2019 | $5.0M2025 | +18.7%/yr | |
| Capex / revenue | 18.7%2019 | 40.5%2025 | +21.8 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ATYR cash flow by activity
OperatingInvestingFinancingChange in cash
ATYR net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
ATYR cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$74.1M | −$64.0M | −$50.4M | −$45.3M | −$33.8M | −$16.2M | −$23.8M | −$34.5M | −$48.2M | −$57.9M |
| Depreciation & amortization | $1.6M | $1.5M | $2.7M | $1.7M | $1.3M | $1.3M | $1.4M | $746,000 | $713,000 | $900,000 |
| Stock-based compensation | $5.0M | $3.0M | $2.6M | $2.2M | $1.6M | $1.5M | $1.8M | — | — | — |
| Change in working capital | $7.5M | −$6.9M | $15.0M | −$833,000 | −$2.6M | −$2.3M | $206,000 | −$1.4M | −$1.7M | −$1.4M |
| Other non-cash items | −$1.9M | −$2.7M | −$3.2M | $441,000 | $363,000 | $453,000 | $395,000 | $4.2M | $6.9M | $5.4M |
| Cash from operating activities | −$62.0M | −$69.1M | −$33.2M | −$41.9M | −$33.1M | −$15.3M | −$20.0M | −$31.1M | −$42.4M | −$52.9M |
| Investing activities | ||||||||||
| Capital expenditures | −$77,000 | −$65,000 | −$4.2M | −$1.6M | −$192,000 | −$202,000 | −$79,000 | −$594,000 | −$1.3M | −$600,000 |
| Investments (net) | −$5.0M | $17.2M | −$20.1M | $47.2M | −$91.6M | $6.9M | — | — | — | — |
| Acquisitions & other investing | $12,000 | $65,000 | $4.2M | $1.6M | $192,000 | $202,000 | $5.0M | $37.8M | −$26.3M | $34.1M |
| Cash from investing activities | −$5.1M | $17.2M | −$20.1M | $47.2M | −$91.6M | $6.9M | $4.9M | $37.2M | −$27.6M | $33.5M |
| Financing activities | ||||||||||
| Net borrowing (repayment) | −$539,000 | −$497,000 | −$394,000 | −$66,000 | $0 | — | — | — | — | — |
| Shares issued | $66.4M | $40.3M | $66.5M | $5.5M | $110.0M | $25.2M | $0 | $0 | $0 | $0 |
| Other financing | $127,000 | $100,000 | $105,000 | $45,000 | $73,000 | −$9.1M | $1.3M | −$4.2M | $52.7M | $4.7M |
| Cash from financing activities | $66.0M | $39.9M | $66.2M | $5.5M | $110.0M | $16.1M | $1.3M | −$4.2M | $52.7M | $4.7M |
| Summary | ||||||||||
| Net change in cash | −$1.0M | −$12.0M | $12.9M | $10.8M | −$14.6M | $7.7M | −$13.8M | $1.9M | −$17.3M | −$14.6M |
| Cash at end of period | $13.0M | $14.0M | $26.0M | $13.1M | $2.3M | $17.0M | $9.2M | $23.0M | $21.1M | $38.4M |
| Free cash flow | −$62.1M | −$69.2M | −$37.4M | −$43.5M | −$33.3M | −$15.5M | −$20.1M | −$31.7M | −$43.7M | −$53.5M |
| Free cash flow margin | −32,664.7% | −29,440.0% | −10,605.1% | −419.1% | — | −148.3% | −4,761.1% | — | — | — |
| Capex / revenue | 40.5% | 27.7% | 1,194.1% | 15.8% | — | 1.9% | 18.7% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$10.3M | −$10.8M | −$14.0M | −$25.7M | −$19.5M | −$14.9M | −$15.0M | −$17.3M | −$16.3M | −$15.5M | −$14.8M | −$11.3M |
| Depreciation & amortization | $405,000 | $394,000 | $394,000 | $389,000 | $387,000 | $383,000 | −$1,000 | $388,000 | $383,000 | $770,000 | $407,000 | $993,000 |
| Stock-based compensation | $1.1M | $1.3M | $1.2M | $1.3M | $1.3M | $1.2M | $770,000 | $752,000 | $727,000 | $740,000 | $659,000 | $664,000 |
| Change in working capital | −$397,000 | −$3.2M | $540,000 | $4.1M | $4.4M | −$1.6M | $1.6M | $3.6M | −$4.5M | −$7.6M | $3.5M | $1.1M |
| Other non-cash items | −$194,000 | −$255,000 | −$373,000 | −$512,000 | −$458,000 | −$523,000 | −$553,000 | −$611,000 | −$735,000 | −$807,000 | −$887,000 | −$979,000 |
| Cash from operating activities | −$9.4M | −$12.5M | −$12.2M | −$20.5M | −$13.9M | −$15.4M | −$13.1M | −$13.2M | −$20.4M | −$22.4M | −$11.1M | −$9.6M |
| Investing activities | ||||||||||||
| Capital expenditures | −$73,000 | −$138,000 | −$31,000 | −$37,000 | −$9,000 | $0 | −$25,000 | −$15,000 | −$8,000 | −$17,000 | −$17,000 | −$557,000 |
| Investments (net) | $15.4M | $11.6M | $16.5M | −$20.4M | $3.3M | −$4.4M | −$6.1M | $17.9M | $6.7M | −$1.4M | $17.8M | $4.4M |
| Acquisitions & other investing | $0 | $0 | $12,000 | $37,000 | $9,000 | $0 | $25,000 | $15,000 | $8,000 | $17,000 | $17,000 | $557,000 |
| Cash from investing activities | $15.3M | $11.5M | $16.4M | −$20.4M | $3.3M | −$4.4M | −$6.1M | $17.9M | $6.7M | −$1.4M | $17.8M | $4.4M |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | $16,000 | — | — | $40,000 | $79,000 | — | — | — | — | — | — | — |
| Net borrowing (repayment) | −$145,000 | −$142,000 | −$139,000 | −$136,000 | −$133,000 | −$131,000 | −$128,000 | −$125,000 | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $29.8M | $17.9M | $18.8M | $18.9M | $20,000 | $13.5M | $7.9M | $6.1M | $2.8M |
| Other financing | $0 | $0 | $8,000 | −$40,000 | $19,000 | $0 | $61,000 | $0 | −$84,000 | −$121,000 | −$75,000 | −$108,000 |
| Cash from financing activities | −$129,000 | −$142,000 | −$131,000 | $29.6M | $17.9M | $18.6M | $18.8M | −$105,000 | $13.4M | $7.7M | $6.0M | $2.7M |
| Summary | ||||||||||||
| Net change in cash | $5.8M | −$1.2M | $4.1M | −$11.2M | $7.3M | −$1.2M | −$378,000 | $4.7M | −$321,000 | −$15.7M | $12.8M | −$2.5M |
| Cash at end of period | $17.7M | $11.8M | $13.0M | $8.9M | $20.1M | $12.8M | $14.0M | $14.4M | $9.7M | $6.8M | $22.5M | $9.8M |
| Free cash flow | −$9.4M | −$12.7M | −$12.2M | −$20.5M | −$13.9M | −$15.4M | −$13.2M | −$13.2M | −$20.5M | −$22.4M | −$11.1M | −$10.1M |
| Free cash flow margin | — | — | — | −10,796.3% | — | — | — | — | — | −9,530.6% | — | −2,865.7% |
| Capex / revenue | — | — | — | 19.5% | — | — | — | — | — | 7.2% | — | 157.8% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
ATYR cash generation
In fiscal 2025 (ended December 31, 2025), aTyr Pharma generated -$62.0 million of cash from operations and spent $0.1 million on capital expenditures, leaving free cash flow of -$62.1 million, −32,664.7% of revenue. Cash and equivalents fell by $1.0 million over the year.
Related: ATYR income statement, ATYR balance sheet. See the ATYR stock overview for the latest quote and news.
ATYR cash flow FAQ
What is aTyr Pharma's free cash flow?
aTyr Pharma's free cash flow was -$62.1 million in fiscal 2025: -$62.0 million of operating cash flow minus $0.1 million of capital expenditures It was -$69.2 million a year earlier..
How much cash does aTyr Pharma generate from operations?
aTyr Pharma generated -$62.0 million of cash from operating activities in fiscal 2025.
How much does aTyr Pharma spend on capital expenditures?
aTyr Pharma spent $0.1 million on capital expenditures in fiscal 2025, 40.5% of revenue, compared with $0.1 million the year before.